§

Ex Parte Platscher et al

14118571 (P.T.A.B. Nov. 24, 2017)
Ex Parte Platscher et al

16 Cited authorities

  1. Amgen Inc. v. Hoechst Marion Roussel, Inc.

    314 F.3d 1313 (Fed. Cir. 2003)   Cited 508 times   14 Legal Analyses
    Holding that “non-naturally occurring” and “not isolated” were structural elements defining the source of the claimed material, rather than steps for obtaining it

  2. Net Moneyin v. Verisign

    545 F.3d 1359 (Fed. Cir. 2008)   Cited 283 times   6 Legal Analyses
    Holding that, to anticipate, a single prior art reference must not only disclose all the limitations claimed but also must disclose those limitations "arranged or combined in the same way as recited in the claim"

  3. In re Gleave

    560 F.3d 1331 (Fed. Cir. 2009)   Cited 149 times
    Finding that the prior art reference was enabling and stating that “the fact that [the reference] provides ‘no understanding of which of the targets would be useful’ is of no import, because [the patent applicant] admits that it is well within the skill of an ordinary person in the art to make any oligodeoxynucleotide sequence”

  4. Eli Lilly & Co. v. Zenith Goldline Pharmaceuticals, Inc.

    471 F.3d 1369 (Fed. Cir. 2006)   Cited 136 times   5 Legal Analyses
    Holding prior art supplied no motivation to modify compound to include claimed structural features because no reasonable expectation of success

  5. Symbol Technologies, Inc. v. Opticon, Inc.

    935 F.2d 1569 (Fed. Cir. 1991)   Cited 149 times   5 Legal Analyses
    Concluding that a party who chooses not to cross-examine a witness on an issue cannot later "recoup for its failed litigation strategy"

  6. Impax v. Aventis Pharma

    545 F.3d 1312 (Fed. Cir. 2008)   Cited 68 times
    Stating that defenses of obviousness and anticipation must be proven by clear and convincing evidence

  7. Novo Nordisk Pharmaceuticals, Inc. v. Bio-Technology General Corp.

    424 F.3d 1347 (Fed. Cir. 2005)   Cited 63 times   2 Legal Analyses
    Holding inventor committed inequitable conduct in writing example in the past tense and failing to inform PTO of failed experiments

  8. Rasmusson v. Smithkline Beecham Corp.

    413 F.3d 1318 (Fed. Cir. 2005)   Cited 43 times   4 Legal Analyses
    Explaining "proof of efficacy is not required in order for a reference to be enabled for purposes of anticipation"

  9. In re Bond

    910 F.2d 831 (Fed. Cir. 1990)   Cited 57 times   1 Legal Analyses
    Finding that, since "structural equivalency ... is a question of fact," where the Board made no finding as to structural equivalency, this Court would "not reach that question in the first instance" and instead vacate and remand

  10. Application of Hafner

    410 F.2d 1403 (C.C.P.A. 1969)   Cited 20 times
    Noting that a fatal defect cannot be cured by an amendment

  11. Section 112 - Specification

    35 U.S.C. § 112   Cited 7,399 times   1051 Legal Analyses
    Requiring patent applications to include a "specification" that provides, among other information, a written description of the invention and of the manner and process of making and using it

  12. Section 103 - Conditions for patentability; non-obvious subject matter

    35 U.S.C. § 103   Cited 6,154 times   485 Legal Analyses
    Holding the party seeking invalidity must prove "the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains."

  13. Section 102 - Conditions for patentability; novelty

    35 U.S.C. § 102   Cited 6,020 times   1020 Legal Analyses
    Prohibiting the grant of a patent to one who "did not himself invent the subject matter sought to be patented"

  14. Section 6 - Patent Trial and Appeal Board

    35 U.S.C. § 6   Cited 187 times   63 Legal Analyses
    Giving the Director authority to designate "at least 3 members of the Patent Trial and Appeal Board" to review "[e]ach appeal, derivation proceeding, post-grant review, and inter partes review"

  15. Section 134 - Appeal to the Patent Trial and Appeal Board

    35 U.S.C. § 134   Cited 98 times   30 Legal Analyses

    (a) PATENT APPLICANT.-An applicant for a patent, any of whose claims has been twice rejected, may appeal from the decision of the primary examiner to the Patent Trial and Appeal Board, having once paid the fee for such appeal. (b) PATENT OWNER.-A patent owner in a reexamination may appeal from the final rejection of any claim by the primary examiner to the Patent Trial and Appeal Board, having once paid the fee for such appeal. 35 U.S.C. § 134 July 19, 1952, ch. 950, 66 Stat. 801; Pub. L. 98-622

  16. Section 1.136 - [Effective until 1/19/2025] Extensions of time

    37 C.F.R. § 1.136   Cited 17 times   30 Legal Analyses

    (a) (1) If an applicant is required to reply within a nonstatutory or shortened statutory time period, applicant may extend the time period for reply up to the earlier of the expiration of any maximum period set by statute or five months after the time period set for reply, if a petition for an extension of time and the fee set in § 1.17(a) are filed, unless: (i) Applicant is notified otherwise in an Office action; (ii) The reply is a reply brief submitted pursuant to § 41.41 of this title; (iii)